Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, today announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting. The Company has received approval from the Drugs Controller General of India (DCGI) […]
Glenmark Pharmaceuticals Launches TEVIMBRA® in India: Expanding Access to Innovative Immuno-Oncology Treatment for Non-Small Cell Lung Cancer and Esophageal Squamous Cell Carcinoma
Glenmark Pharmaceuticals Ltd. (Glenmark) a research-led, global pharmaceutical company, launched TEVIMBRA® (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO). TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. It is indicated for the […]